Ask about this productRelated genes to: ARID2 antibody
- Gene:
- ARID2 NIH gene
- Name:
- AT-rich interaction domain 2
- Previous symbol:
- -
- Synonyms:
- KIAA1557, DKFZp686G052, FLJ30619, BAF200
- Chromosome:
- 12q12
- Locus Type:
- gene with protein product
- Date approved:
- 2004-01-28
- Date modifiied:
- 2016-10-18
Related products to: ARID2 antibody
Related articles to: ARID2 antibody
- Cholangiocarcinoma (CCA) and gallbladder cancer (GBC) exhibit distinct biological behaviors and treatment responses, potentially driven by differences in their genomic landscapes. However, genomic investigations of biliary tract carcinoma (BTC) remain limited. A retrospective analysis was performed on next-generation sequencing data from 258 patients with BTC (188 with CCA, 70 with GBC), with an external cohort from Memorial Sloan-Kettering Cancer Center (MSKCC cohort) included for comparison. The most frequently altered genes in BTC included TP53 (56.6%), KRAS (27.9%), CDKN2A (21.3%), TERT (17.8%), and MCL1 (14.3%). CCA was predominantly characterized by mutations in ARID1A (15.4% vs. 5.7%, P = 0.04) and PBRM1 (10.1% vs. 0%, P = 0.003), as well as MCL1 amplifications (17.0% vs. 5.7%, P = 0.03), while GBC showed higher frequencies of TP53 alterations (78.6% vs. 47.9%, P < 0.001), ARID2 (15.7% vs. 3.7%, P = 0.002), TERT (24.3% vs. 11.2%, P = 0.02), CCNE1 amplifications (21.4% vs. 2.7%, P < 0.001), and SOX2 amplifications (4.3% vs. 0%, P = 0.02). GBC also exhibited an enrichment of alterations in the DNA damage response (DDR) (84.3% vs. 71.3%, P = 0.04) and p53 signaling (88.6% vs. 59.6%, P < 0.001) pathways. Additionally, 39.9% of patients with BTC harbored at least one actionable genomic alteration. Germline variants were detected in 7.0% (18/258) of patients, with the majority occurring in DDR (61.1%) and p53 (22.2%) pathways. Comparisons with the MSKCC cohort revealed similar genomic features and alterations. Patients with CCA exhibited significantly longer overall survival (OS) than patients with GBC (median OS, 41.2 vs. 24.3 months, P = 0.003). In the MSKCC cohort, high tumor mutational burden (TMB-H) correlated with poorer OS (HR = 1.43, P = 0.01), while PBRM1 mutations were associated with improved survival (HR = 0.50, P = 0.02). This study underscores the distinct genomic profiles of GBC and CCA, offering valuable insights into the molecular underpinnings of these aggressive cancers and supporting the development of precision medicine strategies. - Source: PubMed
Publication date: 2026/06/08
Lu WeiqunLiu RujiaoLiu CuicuiPang JiaohuiYin JianiZhang Zhe - The AT-rich interactive domain-containing protein 2 (ARID2) is a core component of the chromatin-remodeling complex that regulates transcription by modulating nucleosome positioning. Here we have characterized six ARID2 commercial antibodies for western blot, immunoprecipitation, and immunofluorescence using a standardized experimental protocol based on comparing read-outs in knockout cell lines and isogenic parental controls. These studies are part of a larger, collaborative initiative seeking to address antibody reproducibility issues by characterizing commercially available antibodies for human proteins and publishing the results openly as a resource for the scientific community. While the use of antibodies and protocols vary between laboratories, we encourage readers to use this report as a guide to select the most appropriate antibodies for their specific needs. - Source: PubMed
Publication date: 2026/04/24
Moleón Vera RuízAlende CharlesFothouhi MaryamBolívar Sara GonzálezAyoubi RihamFrancis VincentMcPherson Peter SLaflamme Carl - Brain metastases in advanced thyroid cancer may be underrecognized due to lack of routine brain imaging. We characterized the clinical and molecular features, risk factors, and survival outcomes of patients with non-anaplastic follicular cell-derived thyroid carcinoma (FCDTC) with brain metastases. - Source: PubMed
Publication date: 2026/05/29
Barron Carly CMegid Thais Baccili CuryDeng YangqingSugumar VijithanLadak SaraMesci AruzYan MichaelLukovic JelenaKrzyzanowska Monika KSawka Anna MMete OzgurMa Lucy X - Gallbladder cancer (GBC), an aggressive disease with limited treatment options, occurs mainly in low-income and middle-income regions of Asia and Latin America. We analysed whole-exome sequencing data from 262 GBC tumour-normal sample pairs from Chilean, Chinese, Indian, Japanese and South Korean patients to investigate differences in GBC mutation profiles according to geographic location and genetic ancestry. - Source: PubMed
Publication date: 2026/05/21
Gárate-Calderón ValentinaKumar RajivMarcelain KatherineZollner LindaBoekstegers FelixBarajas OlgaLoader DenisseRivera María TeresaMorales Erikde Toro GonzaloCaglevic ChristianShibata TatsuhiroLorenzo Bermejo Justo - Lung cancer remains a leading cause of cancer mortality in India, yet its genomic landscape remains understudied. To address this gap, we performed whole-exome sequencing (WES) on tumor and matched blood samples from 47 lung cancer patients [adenocarcinoma (ADC): 30; squamous cell carcinoma (SqCC): 10; and small cell lung cancer (SCLC): 7] to comprehensively analyze somatic mutations across all protein-coding genes. Our analysis revealed novel and recurrent alterations, with being the most recurrently mutated gene, and emerging as the most frequently mutated across subtypes. Shared mutations included and , the latter not previously associated with lung cancer. ADC exhibited the highest mutational diversity, particularly in RTK/MAPK pathway genes (). Notably, mutations were identified in 26.7% of ADC cases, including exon 19 deletions (5 cases), exon 21 missense mutations (2 cases), and exon 20 insertions (3 cases) and a novel exon 20 duplication (p.Ser768_Asp770dup). SqCC showed frequent mutations in and , suggesting a role for epigenetic dysregulation. One SqCC case harbored a rare p.Glu866Gly mutation. SCLC was enriched for (43%) and (14%) mutations, along with alterations in and Importantly, therapeutically actionable mutations were identified in 91.5% patients, including those with NCCN-recommended (25.5%) and FDA-approved off-label drug targets (68.1%). These findings underscore the value of WES in uncovering clinically relevant mutations and support the integration of genomic profiling into precision oncology strategies for Indian lung cancer patients. - Source: PubMed
Publication date: 2025/06/06
D'Souza WendyLokesh K NMahajan NareshMishra RadhaAmirtham UshaRajeev L KKumar Arun